Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/13469
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJankovic, Slobodan-
dc.contributor.authorMarković N.-
dc.contributor.authorLuković K.-
dc.date.accessioned2021-09-24T22:41:44Z-
dc.date.available2021-09-24T22:41:44Z-
dc.date.issued2021-
dc.identifier.issn2046-8954-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/13469-
dc.description.abstractFocal epilepsy is one of the most frequent specific type of epilepsies, with 30% treatment-resistant patients. There are several directions researchers can follow to improve existing treatment of focal epilepsy: synthesis of new compounds with anticonvulsant activity, repurposing drugs approved for other indications, finding drugs targeted to specific genetic and biochemical defects that underlie focal epilepsy syndromes, development of viral vectors for specific gene therapy, creation of devices and methods for suppression of seizures by electrostimulation and development of methods to increase safety of epilepsy surgery. Improvement of efficacy and safety of current therapies is necessary, as well as developing targeted treatment of genetic epilepsy syndromes that will not only suppress seizures, but stop further epileptogenesis.-
dc.rightsrestrictedAccess-
dc.sourcePharmaceutical Patent Analyst-
dc.titleTreating of focal epilepsy: A patent review-
dc.typereview-
dc.identifier.doi10.4155/ppa-2021-0008-
dc.identifier.scopus2-s2.0-85114069291-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

140

Downloads(s)

8

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.